Lucid Diagnostics (LUCD)
Commercializes EsoGuard testing on esophageal cells collected with EsoCheck.
Something off on this page? Send us feedback.
Commercializes EsoGuard DNA testing using esophageal cells collected with EsoCheck. Revenue comes from patient test results, is concentrated in the United States, and is managed as one operating segment.
Commercializes one office-based esophageal cancer-prevention workflow for GERD patients at risk of Barrett's esophagus and esophageal adenocarcinoma. EsoGuard is the DNA test; EsoCheck is the swallowable cell-collection device used to gather lower-esophageal samples.
Revenue comes from patient EsoGuard test results and is concentrated in the United States. The business is managed as a single operating segment, with LucidDx Labs handling the testing workflow rather than a broad diagnostics menu.
Execution depends on reimbursement expansion, especially Medicare coverage, and on continued commercial access to laboratory-developed tests. The company also relies on outside capital while it scales test adoption.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 15, 2026 | Maxim Group | Reiterate | Rating: —Target: — | Target: $2 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $33.4M · Total debt $24.9M · Total assets $38.9M · Shareholders' equity $10.9M
- Revenue
- $1.5M
- Operating income
- −$12.8M
- Net income
- −$11.7M
No dividends on record.
| Institutions | ≈ 30.37% | 61.73M shares | |
|---|---|---|---|
| 118 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.68% | 9.50M shares | |
| 10 holders · as of Apr 13, 2026 | |||
| Other | ≈ 64.95% | 132.01M shares | |
| remainder | |||
203.24M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Alyeska Investment Group, L.P.Institution | 4.36% | 8.86M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 4.12% | 8.37M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.23% | 6.56M | as of Jun 30, 2026 |
Two Seas Capital LPInstitution | 2.95% | 6.00M | as of Jun 30, 2026 |
Masters Capital Management LLCInstitution | 1.97% | 4.00M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Dennis Matheis | director | +245,000 | $1.00 |
- Castle Biosciences
Direct Barrett's esophagus molecular risk-stratification peer
- Abbott
Scaled cancer-screening owner after Exact Sciences acquisition
- Medtronic
Procedure and endoscopy alternative in esophageal workflows
- Guardant Health
Blood-based oncology screening and reimbursement competitor
- Natera
Large cfDNA testing platform competing for oncology diagnostics budgets
- Quest Diagnostics
National lab channel with oncology and advanced diagnostics scale
- Labcorp
Scaled specialty-testing lab competing for diagnostics access
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lucid Diagnostics | $0.8652 | −2.10% | $161.2M | — | — | 29.6 | +26.7% |
| Castle Biosciences | $34.85 | +0.06% | $1.07B | — | — | 3.0 | +20.1% |
| Abbott | $103.69 | −0.03% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| Medtronic | $90.79 | +0.02% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| Guardant Health | $177.17 | +0.03% | $23.33B | — | — | 19.7 | +44.3% |
| Natera | $392.70 | +0.50% | $53.08B | — | — | 19.6 | +37.7% |
| Quest Diagnostics | $234.76 | −0.04% | $27.03B | 26.0 | 20.5 | 2.3 | +10.2% |
| Labcorp | $311.54 | +0.05% | $26.32B | 26.6 | 16.4 | 1.8 | +5.8% |
| Median | 26.3 | 17.2 | 3.1 | +13.7% |